Cell therapy for advanced b-cell lymphoma or leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of cell therapy called CT1194D for people with certain B-cell blood cancers that have not responded to or have come back after standard treatment. The therapy is designed to find and destroy cancer cells that carry the CD19 or CD20 marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of B-cell lymphoma (like large B-cell lymphoma, mantle cell lymphoma, or low-grade follicular lymphoma) or B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not improved after standard treatment.
- Your cancer cells test positive for CD19 or CD20 markers (a sign the treatment might work).
- You need to be in fairly good overall health, with normal liver, kidney, heart, and lung function.
- Women who can still have children must have a negative pregnancy test and agree to use birth control for a year; men must agree to use birth control and not donate sperm for a year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental therapy called CT1195E, a type of 'living drug' made from your own immune cells to fight B-cell cancers that have returned or not responded to standard care. It's a phase 1 study, which means the main goal is to find a safe and effective dose, but you may benefit from the treatment.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This trial tests a new type of CAR T-cell therapy that targets two specific markers (CD19 and CD22) on cancer cells. It is for people ages 1 to 30 with hard-to-treat B-cell leukemia or lymphoma that has not responded to standard treatments.
This study tests an experimental treatment called CT120 (a CAR-T cell therapy) for people with certain types of B-cell lymphoma that have returned or not responded to treatment. CAR-T therapy uses your own immune cells, modified in a lab, to target and destroy cancer cells, and this trial aims to see if it is safe and effective.
This trial tests a new type of immune cell therapy called CAR-T cells that are designed to find and destroy cancer cells with the CD19 or CD22 markers. The goal is to see if this experimental treatment can help people with B-cell acute lymphoblastic leukemia or non-Hodgkin's lymphoma when other treatments haven't worked.
Hear when a new Relapsed/Refractory B-Cell Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.